Literature DB >> 23583494

Stabilization of a recombinant ricin toxin A subunit vaccine through lyophilization.

Kimberly J Hassett1, Megan C Cousins, Lilia A Rabia, Chrystal M Chadwick, Joanne M O'Hara, Pradyot Nandi, Robert N Brey, Nicholas J Mantis, John F Carpenter, Theodore W Randolph.   

Abstract

Lyophilization was used to prepare dry, glassy solid vaccine formulations of recombinant ricin toxin A-chain containing suspensions of colloidal aluminum hydroxide adjuvant. Four lyophilized formulations were prepared by using combinations of rapid or slow cooling during lyophilization and one of two buffers, histidine or ammonium acetate. Trehalose was used as the stabilizing excipient. Aggregation of the colloidal aluminum hydroxide suspension was reduced in formulations processed with a rapid cooling rate. Aluminum hydroxide particle size distributions, glass transition temperatures, water contents, and immunogenicities of lyophilized vaccines were independent of incubation time at 40 °C for up to 15 weeks. Mice immunized with reconstituted ricin toxin subunit A (RTA) vaccines produced RTA-specific antibodies and toxin-neutralizing antibodies (TNAs) regardless of the length of high temperature vaccine storage or the degree of aluminum adjuvant aggregation that occurred during lyophilization. In murine studies, lyophilized formulations of vaccines conferred protection against exposure to lethal doses of ricin, even after the lyophilized formulations had been stored at 40 °C for 4 weeks. A corresponding liquid formulation of vaccine stored at 40 °C elicited RTA-specific antibody titers but failed to confer immunity during a ricin challenge.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Adjuvant; Aggregation; Aluminum; Biodefense; Freeze drying; Lyophilization; Ricin; Stability; Vaccine

Mesh:

Substances:

Year:  2013        PMID: 23583494      PMCID: PMC3797224          DOI: 10.1016/j.ejpb.2013.03.029

Source DB:  PubMed          Journal:  Eur J Pharm Biopharm        ISSN: 0939-6411            Impact factor:   5.571


  39 in total

1.  Preparation and properties of a freeze-dried B.C.G. vaccine of increased stability.

Authors:  J UNGAR; P W MUGGLETON; J A DUDLEY; M I GRIFFITHS
Journal:  Br Med J       Date:  1962-10-27

Review 2.  The history of ricin, abrin and related toxins.

Authors:  Sjur Olsnes
Journal:  Toxicon       Date:  2004-09-15       Impact factor: 3.033

3.  The capacity of particles to increase allergic sensitization is predicted by particle number and surface area, not by particle mass.

Authors:  Unni Cecilie Nygaard; Mari Samuelsen; Audun Aase; Martinus Løvik
Journal:  Toxicol Sci       Date:  2004-09-29       Impact factor: 4.849

4.  Role of aluminum-containing adjuvants in antigen internalization by dendritic cells in vitro.

Authors:  Garry L Morefield; Anna Sokolovska; Dongping Jiang; Harm HogenEsch; J Paul Robinson; Stanley L Hem
Journal:  Vaccine       Date:  2005-02-18       Impact factor: 3.641

Review 5.  Ricin: current understanding and prospects for an antiricin vaccine.

Authors:  Catherine J Marsden; Daniel C Smith; Lynne M Roberts; J Michael Lord
Journal:  Expert Rev Vaccines       Date:  2005-04       Impact factor: 5.217

6.  Moisture transfer from stopper to product and resulting stability implications.

Authors:  M J Pikal; S Shah
Journal:  Dev Biol Stand       Date:  1992

Review 7.  Rational design of stable lyophilized protein formulations: some practical advice.

Authors:  J F Carpenter; M J Pikal; B S Chang; T W Randolph
Journal:  Pharm Res       Date:  1997-08       Impact factor: 4.200

8.  Physical, chemical and immunological stability of CHO-derived hepatitis B surface antigen (HBsAg) particles.

Authors:  D Diminsky; N Moav; M Gorecki; Y Barenholz
Journal:  Vaccine       Date:  1999-08-20       Impact factor: 3.641

9.  Mechanism of freeze-thaw instability of aluminum hydroxycarbonate and magnesium hydroxide gels.

Authors:  M I Zapata; J R Feldkamp; G E Peck; J L White; S L Hem
Journal:  J Pharm Sci       Date:  1984-01       Impact factor: 3.534

10.  Biodegradable and biocompatible poly(DL-lactide-co-glycolide) microspheres as an adjuvant for staphylococcal enterotoxin B toxoid which enhances the level of toxin-neutralizing antibodies.

Authors:  J H Eldridge; J K Staas; J A Meulbroek; T R Tice; R M Gilley
Journal:  Infect Immun       Date:  1991-09       Impact factor: 3.441

View more
  17 in total

1.  Recent advances in the development of vaccines against ricin.

Authors:  Robert N Brey; Nicholas J Mantis; Seth H Pincus; Ellen S Vitetta; Leonard A Smith; Chad J Roy
Journal:  Hum Vaccin Immunother       Date:  2016-01-25       Impact factor: 3.452

2.  Development of a highly thermostable, adjuvanted human papillomavirus vaccine.

Authors:  Kimberly J Hassett; Natalie M Meinerz; Florian Semmelmann; Megan C Cousins; Robert L Garcea; Theodore W Randolph
Journal:  Eur J Pharm Biopharm       Date:  2015-05-18       Impact factor: 5.571

3.  Glassy-state stabilization of a dominant negative inhibitor anthrax vaccine containing aluminum hydroxide and glycopyranoside lipid A adjuvants.

Authors:  Kimberly J Hassett; David J Vance; Nishant K Jain; Neha Sahni; Lilia A Rabia; Megan C Cousins; Sangeeta Joshi; David B Volkin; C Russell Middaugh; Nicholas J Mantis; John F Carpenter; Theodore W Randolph
Journal:  J Pharm Sci       Date:  2015-01-11       Impact factor: 3.534

4.  A method of lyophilizing vaccines containing aluminum salts into a dry powder without causing particle aggregation or decreasing the immunogenicity following reconstitution.

Authors:  Xinran Li; Sachin G Thakkar; Tinashe B Ruwona; Robert O Williams; Zhengrong Cui
Journal:  J Control Release       Date:  2015-02-28       Impact factor: 9.776

5.  The immunogenicity of thin-film freeze-dried, aluminum salt-adjuvanted vaccine when exposed to different temperatures.

Authors:  Sachin G Thakkar; Tinashe B Ruwona; Robert O Williams; Zhengrong Cui
Journal:  Hum Vaccin Immunother       Date:  2017-01-04       Impact factor: 3.452

6.  Thermostable ricin vaccine protects rhesus macaques against aerosolized ricin: Epitope-specific neutralizing antibodies correlate with protection.

Authors:  Chad J Roy; Robert N Brey; Nicholas J Mantis; Kelly Mapes; Iliodora V Pop; Laurentiu M Pop; Stephen Ruback; Stephanie Z Killeen; Lara Doyle-Meyers; Heather S Vinet-Oliphant; Peter J Didier; Ellen S Vitetta
Journal:  Proc Natl Acad Sci U S A       Date:  2015-03-09       Impact factor: 11.205

7.  Single-vial filovirus glycoprotein vaccines: Biophysical characteristics and immunogenicity after co-lyophilization with adjuvant.

Authors:  Kendall B Preston; Teri Ann S Wong; Albert To; Taylor E Tashiro; Michael M Lieberman; Alex Granados; Karen Feliciano; John Harrison; Jake Yalley-Ogunro; Hanne Andersen Elyard; Oreola Donini; Axel T Lehrer; Theodore W Randolph
Journal:  Vaccine       Date:  2021-08-13       Impact factor: 4.169

8.  Thermostable Ebola virus vaccine formulations lyophilized in the presence of aluminum hydroxide.

Authors:  Carly Fleagle Chisholm; Taek Jin Kang; Miao Dong; Kasey Lewis; Madhuri Namekar; Axel T Lehrer; Theodore W Randolph
Journal:  Eur J Pharm Biopharm       Date:  2019-01-28       Impact factor: 5.571

Review 9.  Progress and challenges associated with the development of ricin toxin subunit vaccines.

Authors:  David J Vance; Nicholas J Mantis
Journal:  Expert Rev Vaccines       Date:  2016-04-06       Impact factor: 5.217

Review 10.  Development of thermostable vaccine adjuvants.

Authors:  Yizhi Qi; Christopher B Fox
Journal:  Expert Rev Vaccines       Date:  2021-06-26       Impact factor: 5.683

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.